etanercept
Enbrel (etanercept) is a TNF blocker built as a decoy receptor fused to an antibody fragment. It mops up tumour necrosis factor before it can inflame joints and skin, and is used in rheumatoid arthritis, psoriatic disease, ankylosing spondylitis and plaque psoriasis.
This page is based on FDA prescribing information and the EMA medicine record for etanercept, cross-checked with the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
TNF is a messenger that runs between immune cells shouting "inflame." Enbrel is a field of decoy mailboxes shaped exactly for that messenger. The messages get dropped into the decoys instead of reaching real cells, the alarm never spreads, and swollen joints and skin slowly calm down.
In simple terms
In diseases such as rheumatoid arthritis and psoriasis, the immune system overproduces TNF, a chemical that keeps inflammation going. Etanercept is a biologic medicine made from the body's own TNF receptor joined to part of an antibody. It floats in the blood and binds TNF before the cytokine can reach cells, switching down inflammation, easing pain and swelling and slowing joint damage.
In depth
Etanercept is a recombinant dimeric fusion protein of the extracellular ligand-binding domain of the human p75 TNF receptor linked to the Fc portion of IgG1. Each dimer binds two TNF molecules with high affinity, neutralising soluble TNF-alpha and TNF-beta and preventing engagement of cell-surface TNF receptors. Unlike some monoclonal anti-TNF antibodies, it does not reliably lyse cells bearing membrane TNF, a difference thought to influence its efficacy profile in granulomatous disease.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
TNF is a messenger that runs between immune cells shouting "inflame."
- In diseases such as rheumatoid arthritis and psoriasis, the immune system overproduces TNF, a chemical that keeps inflammation going.
- Etanercept floats in the blood and binds TNF before the cytokine can reach cells.
- The messages get dropped into the decoys instead of reaching real cells, and the alarm never spreads.
- Inflammation is switched down, pain and swelling ease, and joint damage slows.
Target: Tumour necrosis factor (TNF)
A central inflammatory cytokine that recruits and activates immune cells in joints, entheses and skin; neutralising it interrupts the inflammatory loop in several immune diseases.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- Rheumatoid arthritis in adults
- Psoriatic arthritis in adults
- Ankylosing spondylitis in adults
- Chronic moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Polyarticular juvenile idiopathic arthritis in children 2 years of age and older
Approved uses in European Union
EMA- With methotrexate, for moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying anti-rheumatic drugs has been inadequate, or as monotherapy when methotrexate is inappropriate
Official sources
The statements on this page trace back to these records.
- Enbrel (etanercept) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: etanercept prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: etanercept
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.